21 May 2013
Keywords: roche, continue, interleukin-12, trials, hoffmann-la, decided, its
Article | 26 June 1995
Hoffmann-La Roche has decided to continue with its trials of
interleukin-12 in patients with kidney cancer, despite the fact that
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 June 1995
20 May 2013
© 2013 thepharmaletter.com